Ultragenyx Pharmaceutical Inc. (RARE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 55.77 |
| Open | 54.50 |
| Bid | 55.15 x 800 |
| Ask | 55.92 x 1300 |
| Day's Range | 54.35 - 56.41 |
| 52 Week Range | 45.20 - 104.38 |
| Volume | |
| Avg. Volume | 690,187 |
| Market Cap | 3.894B |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RARE
Related Research
- Ultragenyx Pharmaceutical Inc.Daily – Vickers Top Buyers & Sellers for 04/20/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 months agoArgus Research
- Zacks
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up
Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.
- Benzinga
Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance
Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Q2 sales reached $89.3 million, up from $86.97 million a year ago, beating the consensus of $87.51 million. The company recognized $64.0 million in Crysvita (burosumab) revenue in the Ultragenyx territories, including $51.6 million in collaboration revenue in the North American profit share territory and net product sales in other territories regions of $12.4 million. Yoyalty revenue related to European Crysvita sales was $5.4 million. Dojolvi's (tr
- Zacks
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
